Shares of Agilent Technologies Inc (NYSE:A) ended Friday session in green amid volatile trading. The shares closed up +0.01 points or 0.02% at $47.00 with 1.42 million shares getting traded. Post opening the session at $47.23, the shares hit an intraday low of $46.89 and an intraday high of $47.39 and the price vacillated in this range throughout the day. The company has a market cap of $15.30 billion and the numbers of outstanding shares have been calculated to be 324.00 million shares.
Agilent Technologies Inc (A) on August 30, 2016 introduced a new addition to its industry-leading line of gas chromatographs. The Agilent Intuvo 9000 GC solution offers users new innovative technology that will help laboratories meet operational, scientific and financial goals.
Designed together with customers, for customers, the Intuvo 9000 makes complex technology easy to use. Click-and-run connections eliminate ferrules, guard-chip technology extends column life, and the trim-free column eliminates retention time shifts due to column trimming maintenance.
With Intuvo Flow Technology chips and Smart ID Keys, the Intuvo 9000 system self-identifies installed components and self-configures methods. Operations like mid-column backflush are made routine by eliminating complex setup and extra calculators.
The touchscreen user interface provides quick access to system status and real-time data, and it guides the user through routine maintenance operations. Connection via smartphone or tablet notifies laboratory managers remotely of system status.
The new system, especially when coupled with mass spectrometry, is ideal for high-throughput contract laboratories, and for labs dealing with challenging sample matrices in fields such as food, environmental, chemical, pharma and forensics testing.
“We began this innovation journey by listening carefully to our customers around the world,” said Shanya Kane, Agilent vice president and general manager of the company’s Gas Chromatography Division. “The Agilent Intuvo 9000 GC system is so intelligent it will make lab technicians feel like GC experts. Lab managers will appreciate the boost in productivity, and business owners will enjoy improved financial outcomes.”
“Agilent has been the market leader in GC for the past 50 years,” said Mike McMullen, Agilent president and CEO. “With this heritage, coupled with an extensive network of industry partnerships and market experts, Agilent was uniquely positioned to take another leap forward by putting this transformational technology in the hands of our customers.”
Shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) ended Friday session in green amid volatile trading. The shares closed up +0.01 points or 0.64% at $1.57 with 876,867.00 shares getting traded. Post opening the session at $1.58, the shares hit an intraday low of $1.56 and an intraday high of $1.59 and the price vacillated in this range throughout the day. The company has a market cap of $384.38 million and the numbers of outstanding shares have been calculated to be 243.26 million shares.
Arena Pharmaceuticals, Inc. (ARNA) on Sept. 1, 2016 announced the formation of Beacon Discovery Inc. (“Beacon”), an independent, privately-held drug discovery incubator.
Beacon will focus on identifying and advancing molecules targeting G-Protein Coupled Receptors (GCPRs) from concept to clinic leveraging the strengths and capabilities developed over close to two decades at Arena. Beacon plans to engage global pharmaceutical partners to facilitate discovery and early stage development.
Arena will have certain rights to compounds developed by Beacon and will collaborate with Beacon in support of Arena’s proprietary pipeline programs as well as the Boehringer Ingelheim International GmbH collaboration. Additionally, Arena will be entitled to certain rights to potential cash flows generated by Beacon in the future.
“The formation of Beacon underscores both our commitment to transitioning Arena from a historically research-oriented organization to a high-performing clinical development organization and our commitment to maximizing the value of our assets,” said Amit Munshi, CEO of Arena. “We believe that Beacon has the potential to unlock the value of Arena’s historical research platform for the long term benefit of patients and shareholders.”
Dominic P. Behan, Ph.D., D.Sc., Arena’s co-founder, will serve as Beacon’s Chief Executive Officer and transition from being Arena’s Chief Scientific Officer and a member of its Board of Directors to become the Chairman of Arena’s Scientific Advisory Board and a consultant.
“I am grateful for the work that Dominic has delivered in his time at Arena. As one of the co-founders of Arena, Dominic has significantly contributed to Arena’s success and we are pleased that he will continue to participate as Chairman of the Scientific Advisory Board,” said Dr. Tina Nova, Chairman of Arena’s Board of Directors. “Dominic’s knowledge of the clinical programs at Arena will be important as we continue to evolve our business focus.”